Twist Bioscience (TWST) Projected to Post Quarterly Earnings on Monday

Twist Bioscience (NASDAQ:TWST) will likely be announcing its Q3 2026 results before the market opens on Monday, August 3rd. Analysts expect the company to post earnings of ($0.50) per share and revenue of $114.5450 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Monday, August 3, 2026 at 8:00 AM ET.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The firm had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.66) earnings per share. On average, analysts expect Twist Bioscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Twist Bioscience Stock Performance

Shares of TWST stock opened at $90.27 on Monday. The stock has a fifty day moving average price of $81.57 and a 200 day moving average price of $60.29. The stock has a market cap of $5.62 billion, a PE ratio of -67.87 and a beta of 2.11. Twist Bioscience has a 1 year low of $23.30 and a 1 year high of $105.47. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.42 and a current ratio of 2.70.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 291 shares of Twist Bioscience stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $87.32, for a total value of $25,410.12. Following the completion of the sale, the senior vice president owned 120,414 shares in the company, valued at $10,514,550.48. The trade was a 0.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Adam Laponis sold 2,399 shares of Twist Bioscience stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the completion of the sale, the chief financial officer owned 110,276 shares of the company’s stock, valued at $10,402,335.08. This trade represents a 2.13% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 50,211 shares of company stock valued at $4,199,331. Corporate insiders own 3.08% of the company’s stock.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP purchased a new position in Twist Bioscience during the third quarter worth approximately $28,000. National Bank of Canada FI purchased a new stake in shares of Twist Bioscience during the 3rd quarter valued at $46,000. Truvestments Capital LLC increased its holdings in shares of Twist Bioscience by 167.0% during the 4th quarter. Truvestments Capital LLC now owns 1,773 shares of the company’s stock worth $56,000 after buying an additional 1,109 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Twist Bioscience during the 4th quarter worth $58,000. Finally, Smartleaf Asset Management LLC raised its position in shares of Twist Bioscience by 83.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,955 shares of the company’s stock worth $63,000 after buying an additional 887 shares during the period.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Leerink Partners set a $110.00 target price on Twist Bioscience in a report on Thursday, July 16th. TD Cowen boosted their price objective on shares of Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Robert W. Baird increased their price objective on shares of Twist Bioscience from $50.00 to $65.00 and gave the company an “outperform” rating in a research note on Tuesday, May 5th. Guggenheim raised their target price on shares of Twist Bioscience from $60.00 to $107.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, UBS Group set a $89.00 target price on shares of Twist Bioscience in a research report on Monday, June 15th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $90.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.